Divi's Labs Starts Commercial Operations At Kakinada Greenfield Project
Divi's Laboratories Ltd. on Thursday said it has started commercial operations at its Kakinada plant in Andhra Pradesh. The operations are a part of Phase One of Unit 3 of the greenfield project at Ontimamidi Village (Kona) in Thondangi Mandal, Kakinada.
The first phase of 'Export Orientated Unit' is being implemented on 200 acres of the 500-acre Unit III site, with an estimated investment between Rs 1,200 crores and Rs 1,500 crores, according to an exchange filing.
Divi's Labs currently operates two manufacturing sites near Hyderabad and Visakhapatnam. Both the manufacturing units have more than 64 production buildings and 70 pharma suits with a total reaction capacity of more than around 14,500 m³, making it one of the largest active pharmaceutical ingredients manufacturing facilities in the world.
The third manufacturing site near Kakinada has been in the works since 2021.
The company is a commercial-scale manufacturer of non-potent and highly potent APIs as well as several low-dose products.
Divi's Laboratories reported a strong performance in the second quarter, with a 22.5% increase in consolidated revenue, reaching Rs 2,338 crore compared to Rs 1,909 crore in the same period last year.
Net profit also saw a significant rise of 47%, reaching Rs 510 crore, up from Rs 348 crore in the corresponding quarter of the previous year.
Shares of Divi's Labs closed 1.15% higher at Rs 6,140.5 apiece, compared to a 1.8% rise in the benchmark BSE Sensex. The stock gave a return of 52% last year.
Ten out of the 28 analysts tracking Divi's Laboratories have a 'buy' rating on the stock; five recommend a 'hold,' and 13 suggest a 'sell,' according to Bloomberg data. The average of the 12-month analyst price target of Rs 5,456 implies a potential downside of 11%.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.
-
It's Time To Take The GST Council's Bet On Trust Global
Payment records can prove India's services exports, and clear, proportionate rules can bring foreign digital sellers into the tax net.
-
Opinion | India at 38: From Innovation Overperformer to Innovation Powerhouse
India now has 453 VC-backed deep science startups, 18 of them late-stage, after 117 percent growth since 2020. Laurus Labs, at USD 9.3 billion, is the most valuable deep science company in any middle-income economy outside China.
